RecruitingAcute PorphyriasCutaneous Porphyrias
Longitudinal Study of the Porphyrias
Eligible age
All ages
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Sponsor: The American Porphyrias Expert Collaborative
You may qualify if…
- ✓ Individuals with a documented diagnosis of a porphyria.
- ✓ For each type of porphyria, the inclusion criteria are based on
- ✓ Biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing performed after 1980 (Absolute values are preferred for diagnostic biochemical thresholds. Fold increases in comparison to an upper (or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated by considerable variation between laboratories in normal limits. Equivocal biochemical measurements may require confirmation by a consortium reference laboratory;)
- ✓ molecular findings documenting the identification of a mutation in a porphyria-related gene.
- ✓ In addition, an individual or a parent or guardian must be willing to give written informed consent or assent, as appropriate.
- ✓ Provision is made for enrolling relatives who may not have symptoms but have biochemical or molecular documentation of a porphyria, or in the case of recessive disorders carry a disease-related mutation.
You may not qualify if…
- ✕ Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone marrow diseases;
- ✕ Patients with a prior diagnosis of porphyria that cannot be documented by review of existing medical records or repeat biochemical or DNA testing.
Where it's recruiting
Alabama
Birmingham
California
Los Angeles · San Francisco
Florida
Miami
Illinois
Chicago
Massachusetts
Boston
Minnesota
Minneapolis
New York
New York
North Carolina
Charlotte · Winston-Salem
Ohio
Cleveland
Pennsylvania
Philadelphia
Texas
Galveston · Houston
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT01561157 · last updated 2026-05-15